TARX (Tarsier Pharma) Common Stock: $0.01 Mil (As of Dec. 2025)


What is Tarsier Pharma Common Stock?

Tarsier Pharma TARX Common Stock is $0.01 Mil as of Dec. 2025.

Tarsier Pharma's quarterly common stock stayed the same from Dec. 2024 ($0.01 Mil) to Jun. 2025 ($0.01 Mil) and stayed the same from Jun. 2025 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Tarsier Pharma's annual common stock stayed the same from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil) and stayed the same from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.01 Mil).

Tarsier Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Common Stock Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Common Stock
0.01 0.01 0.01

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock 0.01 0.00 0.01 0.01 0.01

Tarsier Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Tarsier Pharma (TARX) has a Common Stock of $0.01 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Common Stock too high?
Tarsier Pharma's current Common Stock is $0.01 Mil.
How does Tarsier Pharma's Common Stock compare to ?
Tarsier Pharma's Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Common Stock is $0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.